Abbott Laboratories (ABT) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Total Cash From Operating Activities Chart for Abbott Laboratories
Abbott Laboratories (ABT) operating cash flow for FY2025 was USD 9.6B, a 11.8% change from FY2024. Abbott Laboratories's operating cash flow grew from USD 959.9M in 1989 to USD 9.6B in 2025 (896.6% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 3.9%, 10-year CAGR of 12.4%, 20-year CAGR of 3.1%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $186.81B
- Implied Share Price
- $107.96
- Enterprise Value
- $209.91B
- Revenue (TTM)
- $46.58B
- EBITDA
- $11.68B
- Profit Margin
- 11.65%
- Trailing P/E
- 34.27
- Forward P/E
- 19.16
- Price/Book (MRQ)
- 3.58
- Price/Sales (TTM)
- 4.04
- EV/EBITDA
- 17.91
- EV/Revenue
- 4.51
- Dividend Yield
- 2.35%
- Book Value
- $29.54
- Free Cash Flow (FY2025)
- $7.39B
- Free Cash Flow Yield
- 3.96%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.